MedTrace Logo

Belatacept for Renal Transplant Recipients With Delayed Graft Function

NCT02134288 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2021-09-23

No results posted yet for this study

Summary

Currently looking for individuals that have received a kidney transplant, are experiencing delayed graft function (DGF), and meet the criteria for study participation.

Conditions

  • Delayed Graft Function

Interventions

DRUG

Belatacept

DRUG

Everolimus

Sponsors & Collaborators

Principal Investigators

  • Jon Von Visger, M.D./Ph.D. · OSU Wexner Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2018-12-11
Completion
2019-01-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02134288 on ClinicalTrials.gov